Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)

OBJECTIVE: To elucidate the clinical impact of humanized CCR4 antibody (mogamulizumab) on adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed the clinical and pathological features and treatment outcomes of aggressive ATL. METHODS: Twenty-two patients (median age: 65 years) with aggres...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawano, Noriaki, Yoshida, Noriaki, Kawano, Sayaka, Arakawa, Fumiko, Miyoshi, Hiroaki, Yamada, Kyohei, Nakashima, Kazutaka, Yoshida, Shuro, Kuriyama, Takuro, Tochigi, Taro, Nakaike, Takashi, Shimokawa, Tomonori, Yamashita, Kiyoshi, Marutsuka, Kousuke, Mashiba, Koichi, Kikuchi, Ikuo, Ohshima, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709313/
https://www.ncbi.nlm.nih.gov/pubmed/30996180
http://dx.doi.org/10.2169/internalmedicine.2513-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709313/
https://www.ncbi.nlm.nih.gov/pubmed/30996180
http://dx.doi.org/10.2169/internalmedicine.2513-18

Ejemplares similares